[{"id":"12474215-8ccb-4758-b817-b0ea028361d5","acronym":"x-МАР","url":"https://clinicaltrials.gov/study/NCT06949982","created_at":"2025-07-19T13:21:59.299Z","updated_at":"2025-07-19T13:21:59.299Z","phase":"Phase 2","brief_title":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes","source_id_and_acronym":"NCT06949982 - x-МАР","lead_sponsor":"Sergey Orlov, MD","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • methotrexate • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/17/2025","start_date":" 03/17/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-05-04"},{"id":"f49513f4-2324-4f1a-bfa6-fcc569055fc2","acronym":"STAR-T","url":"https://clinicaltrials.gov/study/NCT05839951","created_at":"2023-05-03T15:04:35.012Z","updated_at":"2025-02-25T12:29:31.860Z","phase":"","brief_title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","source_id_and_acronym":"NCT05839951 - STAR-T","lead_sponsor":"Bayer","biomarkers":" KRAS • MSI","pipe":"","alterations":" ","tags":["KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-24"},{"id":"19de6cba-154e-407a-90ae-62caa0401945","acronym":"PARERE","url":"https://clinicaltrials.gov/study/NCT04787341","created_at":"2021-03-08T12:53:54.161Z","updated_at":"2025-02-25T14:40:46.384Z","phase":"Phase 2","brief_title":"PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence","source_id_and_acronym":"NCT04787341 - PARERE","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2025-02-14"},{"id":"fa25f52e-d775-44da-9710-a28c3fa442b5","acronym":"MIRAGE","url":"https://clinicaltrials.gov/study/NCT06275919","created_at":"2024-02-23T18:27:39.333Z","updated_at":"2025-02-25T15:14:15.952Z","phase":"Phase 2","brief_title":"Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)","source_id_and_acronym":"NCT06275919 - MIRAGE","lead_sponsor":"Istituto Oncologico Veneto IRCCS","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 09/23/2024","start_date":" 09/23/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-13"},{"id":"01a705ee-a2db-4710-bb93-a7891b551826","acronym":"","url":"https://clinicaltrials.gov/study/NCT04362839","created_at":"2021-01-18T21:05:18.990Z","updated_at":"2025-02-25T17:36:37.220Z","phase":"Phase 1","brief_title":"Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04362839","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Stivarga (regorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 05/27/2020","start_date":" 05/27/2020","primary_txt":" Primary completion: 09/13/2025","primary_completion_date":" 09/13/2025","study_txt":" Completion: 09/13/2025","study_completion_date":" 09/13/2025","last_update_posted":"2025-01-29"},{"id":"7e4e2e3f-9b70-426a-be9f-ac204c406d94","acronym":"","url":"https://clinicaltrials.gov/study/NCT03712943","created_at":"2021-01-18T18:12:03.302Z","updated_at":"2025-02-25T14:27:43.578Z","phase":"Phase 1","brief_title":"Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer","source_id_and_acronym":"NCT03712943","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Stivarga (regorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 10/23/2018","start_date":" 10/23/2018","primary_txt":" Primary completion: 09/01/2021","primary_completion_date":" 09/01/2021","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2025-01-29"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"1cc3eb18-79f5-432b-996d-68c0fa40cdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06772233","created_at":"2025-02-26T06:55:02.549Z","updated_at":"2025-02-26T06:55:02.549Z","phase":"Phase 2","brief_title":"A Study of Regorafenib Combined with Envafolimab for Metastatic Gastrointestinal Stromal Tumors with Kit Gene Exon 17 Mutation That Failed Standard Treatment","source_id_and_acronym":"NCT06772233","lead_sponsor":"Peking University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Stivarga (regorafenib) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-13"},{"id":"8e333d31-cdb1-4edd-a209-db63d88f24e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06087263","created_at":"2023-10-17T15:12:53.355Z","updated_at":"2025-02-25T17:26:29.076Z","phase":"Phase 2","brief_title":"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.","source_id_and_acronym":"NCT06087263","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SDHB","pipe":" | ","alterations":" KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation","tags":["SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/18/2024","start_date":" 06/18/2024","primary_txt":" Primary completion: 07/01/2032","primary_completion_date":" 07/01/2032","study_txt":" Completion: 07/01/2034","study_completion_date":" 07/01/2034","last_update_posted":"2025-01-10"},{"id":"e68b085a-cda1-45b1-b91f-76f776e1e1a1","acronym":"REGOMA-2","url":"https://clinicaltrials.gov/study/NCT06095375","created_at":"2023-10-23T18:13:31.588Z","updated_at":"2025-02-25T17:26:30.027Z","phase":"Phase 1","brief_title":"Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients","source_id_and_acronym":"NCT06095375 - REGOMA-2","lead_sponsor":"Istituto Oncologico Veneto IRCCS","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Stivarga (regorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 10/09/2024","primary_completion_date":" 10/09/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-24"},{"id":"ac4c8720-90f3-4cfe-bd1a-08988315c11c","acronym":"REPROGRAM-01","url":"https://clinicaltrials.gov/study/NCT04534218","created_at":"2021-01-18T21:42:20.525Z","updated_at":"2025-02-25T17:24:47.487Z","phase":"Phase 2","brief_title":"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04534218 - REPROGRAM-01","lead_sponsor":"Centre Hospitalier Universitaire de Besancon","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type • NRAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • Stivarga (regorafenib) • aspirin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 12/13/2023","primary_completion_date":" 12/13/2023","study_txt":" Completion: 12/13/2023","study_completion_date":" 12/13/2023","last_update_posted":"2024-12-20"},{"id":"c515fc0a-eb3f-4509-a7dc-e23a2f9595b0","acronym":"REGO-EWING","url":"https://clinicaltrials.gov/study/NCT05830084","created_at":"2023-04-26T14:04:47.284Z","updated_at":"2025-02-25T17:26:10.222Z","phase":"Phase 1","brief_title":"Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma","source_id_and_acronym":"NCT05830084 - REGO-EWING","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" EWSR1","pipe":"","alterations":" ","tags":["EWSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/16/2023","start_date":" 06/16/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-11-28"},{"id":"411c6656-9452-41f8-a0dc-a43d6083250d","acronym":"KEYNOTE-A91","url":"https://clinicaltrials.gov/study/NCT04701476","created_at":"2021-01-19T20:50:41.794Z","updated_at":"2025-02-25T16:11:01.325Z","phase":"Phase 2","brief_title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","source_id_and_acronym":"NCT04701476 - KEYNOTE-A91","lead_sponsor":"Teclison Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • Tirazone (tirapazamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-22"},{"id":"76a5691d-3c36-403e-ae0a-2107bdb5f547","acronym":"LEAP-017","url":"https://clinicaltrials.gov/study/NCT04776148","created_at":"2021-03-01T13:52:36.340Z","updated_at":"2025-02-25T13:35:46.773Z","phase":"Phase 3","brief_title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","source_id_and_acronym":"NCT04776148 - LEAP-017","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 480","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 02/20/2023","primary_completion_date":" 02/20/2023","study_txt":" Completion: 09/27/2024","study_completion_date":" 09/27/2024","last_update_posted":"2024-10-29"},{"id":"5fdb4cb2-0fd9-4c4f-bbbb-cd6fb41766da","acronym":"REGPEM-CRC-01","url":"https://clinicaltrials.gov/study/NCT06006923","created_at":"2023-08-23T15:10:55.323Z","updated_at":"2025-02-25T17:26:21.935Z","phase":"Phase 2","brief_title":"Regorafenib in Combination with Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer","source_id_and_acronym":"NCT06006923 - REGPEM-CRC-01","lead_sponsor":"Ibrahim Halil Sahin","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 06/26/2024","start_date":" 06/26/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-10-02"},{"id":"5cf6a85f-90aa-4baa-95e1-1435def27de3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06558773","created_at":"2025-02-27T08:09:23.735Z","updated_at":"2025-02-27T08:09:23.735Z","phase":"Phase 2","brief_title":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","source_id_and_acronym":"NCT06558773","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" CD8 • IL6 • TNFA • CD4 • IL2","pipe":"","alterations":" ","tags":["CD8 • IL6 • TNFA • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2024-08-21"},{"id":"75a2f882-37f5-404f-a62e-867c007e7b0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06543836","created_at":"2025-02-27T08:03:16.048Z","updated_at":"2025-02-27T08:03:16.048Z","phase":"Phase 2","brief_title":"ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer","source_id_and_acronym":"NCT06543836","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Stivarga (regorafenib) • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-08-08"},{"id":"12184ad4-55f3-4772-94db-b7cb72b11565","acronym":"","url":"https://clinicaltrials.gov/study/NCT06454409","created_at":"2024-06-15T04:10:02.028Z","updated_at":"2024-07-02T16:34:26.887Z","phase":"Phase 1","brief_title":"Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06454409","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Stivarga (regorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/20/2025","start_date":" 03/20/2025","primary_txt":" Primary completion: 02/17/2027","primary_completion_date":" 02/17/2027","study_txt":" Completion: 02/17/2027","study_completion_date":" 02/17/2027","last_update_posted":"2024-06-12"},{"id":"6a7437dd-1b7b-49b8-8341-ff9ad04a3230","acronym":"C-800-25","url":"https://clinicaltrials.gov/study/NCT05608044","created_at":"2022-11-08T15:56:56.796Z","updated_at":"2024-07-02T16:34:59.296Z","phase":"Phase 2","brief_title":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","source_id_and_acronym":"NCT05608044 - C-800-25","lead_sponsor":"Agenus Inc.","biomarkers":" EGFR • BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["EGFR • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-06-04"},{"id":"f7adec30-958d-4721-9a82-00722f4075ec","acronym":"PULSE","url":"https://clinicaltrials.gov/study/NCT03992456","created_at":"2021-01-18T19:37:42.598Z","updated_at":"2024-07-02T16:35:02.247Z","phase":"Phase 2","brief_title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","source_id_and_acronym":"NCT03992456 - PULSE","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 10/07/2024","study_completion_date":" 10/07/2024","last_update_posted":"2024-05-21"},{"id":"d6aaa5d1-601e-464f-bad3-4724818101a8","acronym":"INTEGRATEIIb","url":"https://clinicaltrials.gov/study/NCT04879368","created_at":"2023-07-21T01:09:24.991Z","updated_at":"2025-02-25T14:15:58.655Z","phase":"Phase 3","brief_title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","source_id_and_acronym":"NCT04879368 - INTEGRATEIIb","lead_sponsor":"Australasian Gastro-Intestinal Trials Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • albumin-bound paclitaxel • Stivarga (regorafenib) • irinotecan • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-15"},{"id":"2d427c2c-44b2-4d75-9818-a28e1db0dc01","acronym":"CodeBreak 300","url":"https://clinicaltrials.gov/study/NCT05198934","created_at":"2022-01-20T15:53:54.576Z","updated_at":"2024-07-02T16:35:04.260Z","phase":"Phase 3","brief_title":"Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation","source_id_and_acronym":"NCT05198934 - CodeBreak 300","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Lumakras (sotorasib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 03/12/2025","primary_completion_date":" 03/12/2025","study_txt":" Completion: 03/12/2025","study_completion_date":" 03/12/2025","last_update_posted":"2024-05-13"},{"id":"2ffdf6d6-d9b4-4d82-87df-b8731e5b67ba","acronym":"ARYA3","url":"https://clinicaltrials.gov/study/NCT04864054","created_at":"2021-04-28T12:52:53.604Z","updated_at":"2024-07-02T16:35:05.862Z","phase":"Phase 2","brief_title":"T-Cell Therapy (ECT204) in Adults With Advanced HCC","source_id_and_acronym":"NCT04864054 - ARYA3","lead_sponsor":"Eureka Therapeutics Inc.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Stivarga (regorafenib) • ECT204"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-06"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"}]